Leerink Partnrs Has Negative Forecast for KYTX Q3 Earnings

Key Points

• Analysts at Leerink Partners have reduced their Q3 2025 earnings estimates for Kyverna Therapeutics from ($0.76) to ($0.86) per share.
• Kyverna Therapeutics reported a quarterly EPS of ($0.97), slightly exceeding the consensus estimate of ($1.00).
• The company receives a buy rating from five research analysts, with an average price target of $15.60.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for Kyverna Therapeutics in a report released on Tuesday, August 12th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.76). The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.63) EPS, FY2026 earnings at ($3.37) EPS, FY2027 earnings at ($4.03) EPS, FY2028 earnings at ($4.14) EPS and FY2029 earnings at ($3.38) EPS.

A number of other analysts also recently issued reports on the stock. HC Wainwright upgraded shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $4.00 to $5.00 in a report on Tuesday, May 27th. William Blair started coverage on shares of Kyverna Therapeutics in a report on Wednesday. They set an "outperform" rating for the company. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $15.60.

Kyverna Therapeutics Stock Up 4.1%

Kyverna Therapeutics stock traded up $0.1350 during midday trading on Friday, hitting $3.4350. 151,616 shares of the stock were exchanged, compared to its average volume of 370,620. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $8.78. The stock has a market capitalization of $148.55 million, a price-to-earnings ratio of -0.93 and a beta of 3.05. The business's 50-day moving average price is $3.44 and its 200-day moving average price is $2.79.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.03.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Phoenix Wealth Advisors purchased a new stake in Kyverna Therapeutics during the 2nd quarter valued at about $32,000. Catalyst Funds Management Pty Ltd purchased a new stake in Kyverna Therapeutics during the 2nd quarter valued at about $37,000. Squarepoint Ops LLC purchased a new stake in Kyverna Therapeutics during the 4th quarter valued at about $43,000. Qube Research & Technologies Ltd purchased a new stake in Kyverna Therapeutics during the 2nd quarter valued at about $43,000. Finally, Corton Capital Inc. purchased a new stake in Kyverna Therapeutics during the 4th quarter valued at about $45,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.